ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr.

PharmAla will seek to finalize the license and data sharing agreement prior to the conclusion of the 2024 calendar year. The identity of the trial Principal Investigators and institution is currently ...

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the completion of the dosing and initial follow-up period for ...

at 08:10 ICON plc to Present at the Jefferies London Healthcare Conference ICON plc, a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, ...

NASHVILLE, Tenn., November 12, 2024--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI), one of the world’s leading ...

The National Institute of Aging awarded a $7.3 million research grant for the study of NU-9 as a treatment for ...

The vaccine appears to be safe and effective against triple-negative breast cancer -- a type that can’t be treated with ...

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced a new enterprise agreement with Bioforum, a biometrics CRO that ...

The funding will make the hospital's new MRI truly state-of-the-art by adding new imaging methods, allowing users to see more ...

Diabetes is the eighth leading cause of death in the US and can lead to other conditions, including kidney failure, ...

"The entertainment value will be epic," the billionaire said.

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis.